Middle East, North Africa, Afghanistan & Pakistan vs Portugal: Antiretroviral therapy coverage for PMTCT
Middle East, North Africa, Afghanistan & Pakistan
24.6%
in 2019
Portugal
96.0%
in 2009
Middle East, North Africa, Afghanistan & Pakistan rank
13th
Portugal rank
15th
Antiretroviral therapy coverage for PMTCT over time
- Middle East, North Africa, Afghanistan & Pakistan
- Portugal
How they compare
Portugal currently reports 96.0% against 24.6% in Middle East, North Africa, Afghanistan & Pakistan, a difference of 71.4%.
That makes Portugal's figure about 3.9 times Middle East, North Africa, Afghanistan & Pakistan's.
Across all 10 years both countries report, Portugal has been ahead every year.
Middle East, North Africa, Afghanistan & Pakistan ranks 13th and Portugal ranks 15th of 15 groups.
Portugal has averaged higher in every one of the 1 decades both report.
Frequently asked questions
- Which has higher antiretroviral therapy coverage for pmtct, Middle East, North Africa, Afghanistan & Pakistan or Portugal?
- Portugal, at 96.0% against 24.6% in Middle East, North Africa, Afghanistan & Pakistan as of 2009.
- What is the difference in antiretroviral therapy coverage for pmtct between Middle East, North Africa, Afghanistan & Pakistan and Portugal?
- 71.4%, with Portugal ahead.
- How many years of comparable data are there for Middle East, North Africa, Afghanistan & Pakistan and Portugal?
- 10 years are reported by both, from 2000 to 2009.
- How do Middle East, North Africa, Afghanistan & Pakistan and Portugal rank globally for antiretroviral therapy coverage for pmtct?
- Middle East, North Africa, Afghanistan & Pakistan ranks 13th and Portugal ranks 15th of 15 groups.
- Where does this data come from?
- UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT).